MetaVia Forms Strategic Alliance with Syntekabio for DA-1241
MetaVia Inc. (Nasdaq: MTVA), a biotechnology firm renowned for advancing treatments for cardiometabolic diseases, has embarked on a promising research partnership with Syntekabio, a forefront player in AI-powered drug development. This collaboration aims to identify new disease targets and enhance the therapeutic capabilities of DA-1241, MetaVia's innovative oral G-Protein-Coupled Receptor 119 (GPR119) agonist.
Breakthroughs in DA-1241 Clinical Trials
The partnership comes in light of encouraging outcomes from MetaVia's recent Phase 2a clinical trial, which demonstrated that DA-1241 has a strong safety profile and offers both hepatoprotective and glucose-regulating benefits for patients dealing with metabolic dysfunction-associated steatohepatitis (MASH). The trial involving 109 participants spanned 16 weeks, showcasing the compound's potential as a therapeutic agent.
President and CEO of MetaVia, Hyung Heon Kim, expressed optimism about the collaboration, emphasizing that the favorable results from the trial provide a solid foundation for exploring the drug's broader therapeutic range. The partnership will utilize Syntekabio’s advanced DeepMatcher® platform, which leverages AI to conduct extensive virtual screenings across about 1,700 validated protein targets. This methodological approach aims to discover new indications for DA-1241 while ensuring the specificity and reducing off-target interaction risks.
The Therapeutic Potentials of DA-1241
DA-1241 represents a promising advancement in pharmacotherapy for diabetes and MASH. As a GPR119 agonist, it stimulates the release of vital gut peptides such as GLP-1, GIP, and PYY. These peptides play essential roles in regulating glucose levels, fat metabolism, and supporting weight loss. Research highlights DA-1241's beneficial impact on the glucose and lipid profiles as well as its potential to alleviate liver inflammation, all of which were confirmed through preclinical studies.
Notably, the drug has demonstrated a remarkable ability to reduce hepatic steatosis and improve glycemic control in various preclinical animal models. Clinical trials further substantiated DA-1241’s effectiveness, showing positive outcomes in Phase 1 and Phase 2 trials, where the medication was well tolerated among participants, both healthy individuals and those diagnosed with type 2 diabetes mellitus (T2DM).
About Syntekabio’s AI Innovations
Syntekabio Co., Ltd., established in 2009, specializes in merging biology with artificial intelligence (AI) and machine learning (ML) to expedite the discovery of innovative drug compounds. Complemented by a robust global network of contract research organizations, Syntekabio’s advanced computational approaches support the rapid development of new pharmacotherapies. Their adaptable platform continually generates leads and drug candidates tailored to meet client requirements.
MetaVia's Broader Goals in Cardiometabolic Health
Alongside DA-1241, MetaVia is actively developing DA-1726, an oxyntomodulin analogue designed to target obesity. This compound functions as a dual agonist for GLP-1 and glucagon receptors, aiming to enhance body weight reduction results compared to traditional GLP-1 receptor agonists. In clinical assessments, DA-1726 exhibited strong efficacy in improving weight loss, glucose management, and reducing waist circumference, pointing toward its best-in-class potential.
With the promising developments of DA-1241 and the synergistic collaboration with Syntekabio, MetaVia is committed to addressing significant unmet needs in the treatment landscape of metabolic diseases. The combination of robust clinical and AI-guided approaches positions MetaVia to significantly impact patient outcomes in the cardiometabolic space.
Frequently Asked Questions
What is the main goal of the collaboration between MetaVia and Syntekabio?
The partnership aims to identify additional therapeutic indications for DA-1241 and optimize its efficacy using Syntekabio's AI-driven platform.
What are the benefits of DA-1241?
DA-1241 is designed to improve glucose control, enhance lipid profiles, and mitigate liver inflammation, making it a potent option for treating MASH and type 2 diabetes.
How did MetaVia's clinical trials for DA-1241 perform?
The trials showcased a favorable safety profile and demonstrated significant efficacy in managing metabolic dysfunctions among participants.
What is Syntekabio known for in the biotech industry?
Syntekabio is recognized for integrating AI and ML in drug discovery, ensuring rapid and effective development of innovative therapeutic compounds.
What other products is MetaVia developing?
In addition to DA-1241, MetaVia is working on DA-1726, which targets obesity and combines GLP-1 receptor and glucagon receptor agonism for enhanced results.
